Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - linezolid - film-coated tablet - linezolid 600 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 40 mg - capsule, enteric - excipient ingredients: crospovidone; glyceryl monostearate; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; purified talc; hyprolose; mannitol; sodium hydroxide; sucrose; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 20 mg - capsule, enteric - excipient ingredients: glyceryl monostearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; hyprolose; crospovidone; triethyl citrate; purified talc; sodium hydroxide; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - esomeprazole magnesium, quantity: 44.5 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: crospovidone; hyprolose; sodium lauryl sulfate; mannitol; povidone; purified talc; macrogol 6000; methacrylic acid copolymer; triethyl citrate; glyceryl monostearate; polysorbate 80; titanium dioxide; microcrystalline cellulose; sodium stearylfumarate; hypromellose; iron oxide yellow; iron oxide red; macrogol 400; maize starch; sucrose; macrogol 8000 - noxicid is indicated for: gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis. - long-term management of patients with healed oesophagitis to prevent relapse. - symptomatic treatment of gastro-oesophageal reflux disease (gord). patients requiring nsaid therapy. - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori. - eradication of helicobacter pylori in patients

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole magnesium, quantity: 22.252 mg - capsule, enteric - excipient ingredients: triethyl citrate; polysorbate 80; sodium hydroxide; glyceryl monostearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); sucrose; hyprolose; crospovidone; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - for relief of frequent heartburn and other symptoms of gastro-oesophageal reflux disease.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

xixia -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

xixia -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

xixia -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

xixia -